REG - Oncimmune Hldngs PLC - Total Voting Rights

Oncimmune HoldingsAnnouncement

20/12/2021 15:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211220:nRST2462Wa&default-theme=true

RNS Number : 2462W  Oncimmune Holdings PLC  20 December 2021

20 December 2021

 

 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

Total Voting Rights

 

 

In accordance with the Disclosure Guidance and Transparency Rules (DTR 5.6),
Oncimmune makes the following disclosure with respect to the share capital and
voting rights of the Company.

 

Pursuant to the Company's existing block admission, and following the exercise
of options over 15,899 ordinary shares in aggregate during November 2021 by
current and former employees, as at 30 November 2021, the Company's issued
share capital was 69,137,848 ordinary shares of £0.01 each with voting
rights. The Company does not hold any shares in treasury.

 

The above figure as at 30 November 2021 of 69,137,848 may be used by
shareholders as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a change to
their interest in the Company under the FCA's Disclosure Guidance and
Transparency Rules.

 

For further information:

 

Oncimmune Holdings plc

Ron Kirschner, Company Secretary

contact@oncimmune.co.uk (mailto:contact@oncimmune.co.uk)

 

N+1 Singer (Nominated Adviser and Joint Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

+44 (0)20 7496 3000

 

WG Partners (Joint Broker)

David Wilson, Nigel Barnes

+44 (0)203 705 9321

 

Media enquiries:

FTI Consulting

Ben Atwell, Michael Trace, Alex Davis

Oncimmune@fticonsulting.com (mailto:Oncimmune@fticonsulting.com)

+44 (0)20 3727 1000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVREASAEAFAFFFA